Pain occurring as a consequence of vasocclusive events is the most frequent complaint leading to hospitalization of patients with sickle cell disease (SCD). To date, basic studies have focused on the role of red cell sickling and on the interactions of erythrocytes with endothelium in the initiation and propagation of vascular occlusion. Attention now is turning towards the role of other blood cells, e.g. platelets and neutrophils, and on activation of the coagulation system in the pathophysiology of vasoocclusion. Although activation of the complement system in patients with sickle cell anemia has been reported by a number of investigators, the role of complement activations has been completely ignored in basic studies on the pathogenesis of vasoocclusion. The potential importance of complement in this process is underscored by studies demonstrating the ability of complement activation to increase expression of several different endothelial adhesion molecules and to increase expression of tissue factor on both monocytes and endothelial cells. Recent data have shown that loss of normal cell membrane phospholipid asymmetry resulting in the accumulation of phosphatidylserine (PS) in the outer membrane leaflet causes both erythrocytes and activated platelets to become activators of the alternative pathway of complement, resulting in the deposition of C3b on the membranes of these cells. These findings are relevant to SCD because both activated platelets and a subset of erythrocytes that express PS have been found circulating in the blood of patients with sickle cell anemia. Based on these findings, the hypothesis that complement activation could play a vital role in the pathophysiology of vasoocclusion in patients with SCD will be examined.
The aims of the research are as follows. First, to examine the effect of complement activation on endothelial cell expression of adhesion molecules and tissue factor using PS-expressing cells generated in vitro or PS-expressing cells from patients with sickle cell disease to activate complement. Second, to characterize the role of C3b deposition on PS-expressing cells on cell-to- cell adhesion as it relates to the formation of cellular aggregates and the level of tissue factor expression by peripheral blood monocytes. Third, to examine cells isolated from the peripheral blood of SCD patients for the presence of complement activation products and to define the factors that influence the deposition of these molecules on the cells. The results of these studies should provide important new insights into the pathogenesis of vasoocclusion and the potential use of pharmacologic complement blockade in its treatment.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Comprehensive Center (P60)
Project #
5P60HL020985-23
Application #
6325899
Study Section
Project Start
2000-04-01
Project End
2001-03-31
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
23
Fiscal Year
2000
Total Cost
$232,867
Indirect Cost
Name
University of California San Francisco
Department
Type
DUNS #
073133571
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Goodman, Jessica; Hassell, Kathryn; Irwin, David et al. (2014) The splenic syndrome in individuals with sickle cell trait. High Alt Med Biol 15:468-71
James, Ellen Butensky; Vreman, Hendrik J; Wong, Ronald J et al. (2010) Elevated exhaled carbon monoxide concentration in hemoglobinopathies and its relation to red blood cell transfusion therapy. Pediatr Hematol Oncol 27:112-21
Jenkins, Zandra A; Hagar, Ward; Bowlus, Christopher L et al. (2007) Iron homeostasis during transfusional iron overload in beta-thalassemia and sickle cell disease: changes in iron regulatory protein, hepcidin, and ferritin expression. Pediatr Hematol Oncol 24:237-43
Styles, Lori A; Abboud, Miguel; Larkin, Sandra et al. (2007) Transfusion prevents acute chest syndrome predicted by elevated secretory phospholipase A2. Br J Haematol 136:343-4
Kuypers, Frans A; Larkin, Sandra K; Emeis, Jef J et al. (2007) Interaction of an annexin V homodimer (Diannexin) with phosphatidylserine on cell surfaces and consequent antithrombotic activity. Thromb Haemost 97:478-86
Neumayr, Lynne D; Aguilar, Christine; Earles, Ann N et al. (2006) Physical therapy alone compared with core decompression and physical therapy for femoral head osteonecrosis in sickle cell disease. Results of a multicenter study at a mean of three years after treatment. J Bone Joint Surg Am 88:2573-82
Wilson, Leslie S; Moskowitz, Judith Tedlie; Acree, Michael et al. (2005) The economic burden of home care for children with HIV and other chronic illnesses. Am J Public Health 95:1445-52
Vichinsky, Elliott; Butensky, Ellen; Fung, Ellen et al. (2005) Comparison of organ dysfunction in transfused patients with SCD or beta thalassemia. Am J Hematol 80:70-4
Pakbaz, Zahra; Fischer, Roland; Treadwell, Marsha et al. (2005) A simple model to assess and improve adherence to iron chelation therapy with deferoxamine in patients with thalassemia. Ann N Y Acad Sci 1054:486-91
Fricke, Britta; Jarvis, Helen G; Reid, Cecil D L et al. (2004) Four new cases of stomatin-deficient hereditary stomatocytosis syndrome: association of the stomatin-deficient cryohydrocytosis variant with neurological dysfunction. Br J Haematol 125:796-803

Showing the most recent 10 out of 207 publications